Compare Nuvalent Inc (NUVL) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Skyworks Solutions Inc — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Skyworks Solutions Inc trades at $62.75 (market cap $8.99B). The key difference: Nuvalent Inc and Skyworks Solutions Inc are close in size by market cap, and Skyworks Solutions Inc pays a 4.75% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| NUVL | SWKS | |
|---|---|---|
Market Cap | $9.81B | $8.99B |
Sector | Technology | Technology |
52-Week High | $123.96 | $83.40 |
52-Week Low | $72.16 | $52.50 |
Enterprise Value | $8.52B | $8.76B |
Dividend Yield | — | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
Skyworks Solutions (SWKS) trades at $62.95, up 6.14% on the day, with a bearish technical signal but strong fundamental valuation metrics including a P/E of 24.91 and P/S of 2.22. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Recent news highlights ongoing investigations into corporate governance alongside positive coverage of its EV and AI semiconductor innovations.
The stock presents a mixed outlook: analyst consensus is bullish with a $75.88 price target (35 Buy, 23 Hold, 2 Sell), but risks include declining revenue trends (2025: $4.09B, 2026 est: $4.0B), margin compression, and legal scrutiny. Near-term catalysts depend on Q2 earnings beat potential and EV/AI segment growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
